Senti Bio Appoints Feng Hsiung to Board of Directors

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][5] - The company aims to create therapies with enhanced precision and control to treat patients with incurable diseases [5] Leadership Appointment - Feng Hsiung has been appointed to the Board of Directors, effective March 7, 2025, bringing extensive experience in investment strategy and capital markets [2][3] - Hsiung is the Founder, Chief Investment Officer, and CEO of Acion Partners, with a background that includes leadership roles at York Capital [2] Stock Options Grant - On March 7, 2025, the Board granted stock options to three new employees, totaling 202,700 shares at an exercise price of $3.52 per share [4] - The majority of these options, 174,200, were awarded to the new Chief Financial Officer, Jay Cross, under the 2022 Inducement Equity Plan [4] Product Pipeline - Senti Bio's lead program, SENTI-202, targets hematologic cancers and has shown promising initial clinical data, with two out of three patients achieving MRD-negative complete remissions [5] - The company is also advancing its Gene Circuits technology in T cells and exploring applications beyond oncology [5]